fluticasone furoate/vilanterol vs Umeclidinium/Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline
fluticasone furoate/vilanterol · Breo Ellipta
Marketed by GlaxoSmithKline
NCT01313676 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 16,568 participants, with all-cause mortality as an objective clinical primary endpoint. However, the fluticasone furoate/vilanterol versus placebo comparison did not meet statistical significance (hazard ratio 0.878, p=0.137), and the record does not report a power calculation.
Reported efficacy
Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Placebo — Dead: 275 Participants; Alive: 3832 Participants; Unknown: 4 Participants | Fluticasone Furoate 100 µg — Dead: 251 Participants; Alive: 3884 Participants; Unknown: 0 Participants | Vilanterol 25 µg — Dead: 265 Participants; Alive: 3853 Participants; Unknown: 0 Participants | Fluticasone Furoate/Vilanterol 100/25 µg — Dead: 246 Participants; Alive: 3874 Participants; Unknown: 1 Participants (missed)
Result source: NCT01313676
Umeclidinium/Vilanterol
Marketed by GlaxoSmithKline and partners
NCT01777334 · Phase 3 · completed
The trial randomly assigned 905 participants and used double blinding with tiotropium as an active comparator. Its primary endpoint was the clinical lung-function measure trough FEV1, and the primary comparison significantly favored umeclidinium/vilanterol.
Reported efficacy
Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): UMEC/VI 62.5/25 µg 0.205 Liters (Standard Error 0.0114) vs TIO 18 µg 0.093 Liters (Standard Error 0.0115) (met)
Result source: NCT01777334
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | fluticasone furoate/vilanterol | Umeclidinium/Vilanterol |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not reported | —Trial running · NCT06474039 |
| Trough FEV1, change | —Not reported | 0.2 vs 0.1vs TIONCT017773343 other results
|
| SGRQ total, change | —Not reported | —Trial running · NCT06474039 |
| TDI focal score | —Not reported | —Trial running · NCT06474039 |
Moderate or severe exacerbations, annualised rate
- fluticasone furoate/vilanterol
- —Not reported
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
Trough FEV1, change
- fluticasone furoate/vilanterol
- —Not reported
- Umeclidinium/Vilanterol
- 0.2 vs 0.1vs TIONCT01777334
3 other results
- 0.1 vs -0.0 NCT01899742
- 0.2 vs 0.2 NCT02487446
- 0.2 vs 0.2 NCT02487446
SGRQ total, change
- fluticasone furoate/vilanterol
- —Not reported
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
TDI focal score
- fluticasone furoate/vilanterol
- —Not reported
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. fluticasone furoate/vilanterol: 0 of 4 rows · Umeclidinium/Vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Umeclidinium/Vilanterol |
|---|---|
| Dropout rate | 11.7%62.5/25 µga NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results—62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 — NCT02487446 · Phase 3 · registry result, not featured evidence —27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 6.9%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 4%62.5/25 µga NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results—62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 — NCT02487446 · Phase 3 · registry result, not featured evidence —27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 2%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 3.5%62.5/25 µga NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results1.7%62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 3.8% NCT02487446 · Phase 3 · registry result, not featured evidence 5%27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 2.8%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence 0.5%62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 62.5/25 µga headache 8.8% nasopharyngitis 6.2% cough 2.9% NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results62.5/25 µg once daily nasopharyngitis 4% headache 3.5% NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 chronic obstructive pulmonary disease 10.6% nasopharyngitis 5.6% oropharyngeal pain 2.9% NCT02487446 · Phase 3 · registry result, not featured evidence 27.5/12.5 Bid chronic obstructive pulmonary disease 14.8% bronchitis 3.3% sinusitis 1.8% NCT02487498 · Phase 3 · registry result, not featured evidence 62.5/25 µg nasopharyngitis 7.3% headache 6.5% NCT01899742 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Umeclidinium/Vilanterol
show 3 more results
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/vilanterol's landscape · Umeclidinium/Vilanterol's landscape